Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Anemia

Phase 3

Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia

TerminatedNCT00517881

Hoffmann-La RocheAnemia

Start: 2007-06-30End: 2009-11-30Updated: 2016-05-27

A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia

CompletedNCT00699348

Hoffmann-La RocheAnemia

Start: 2008-07-31End: 2010-07-31Updated: 2016-04-06

Related Papers

Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.

2016-03-106 citations